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The functions of caveolae andor caveolins in intact animals are
beginning to be explored. Here, by using endothelial cell-specific
transgenesis of the caveolin-1 (Cav-1) gene in mice, we show the
critical role of Cav-1 in several postnatal vascular paradigms. First,
increasing levels of Cav-1 do not increase caveolae number in the
endothelium in vivo. Second, despite a lack of quantitative changes in
organelle number, endothelial-specific expression of Cav-1 impairs
endothelial nitric oxide synthase activation, endothelial barrier func-
tion, and angiogenic responses to exogenous VEGF and tissue isch-
emia. In addition, VEGF-mediated phosphorylation of Akt and its
substrate, endothelial nitric oxide synthase, were significantly re-
duced in VEGF-treated Cav-1 transgenic mice, compared with WT
littermates. The inhibitory effect of Cav-1 expression on the Akt-
endothelial nitric oxide synthase pathway was specific because VEGF-
stimulated phosphorylation of mitogen-activated protein kinase
(ERK12) was elevated in the Cav-1 transgenics, compared with
littermates. These data strongly support the idea that, in vivo, Cav-1
may modulate signaling pathways independent of its essential role in
caveolae biogenesis.
nitric oxide  caveolae  VEGF  signal transduction
Caveolae are 50- to 100-nm flask-shaped invaginations of theplasma membrane (1) and are present in most mammalian
cells. The putative functions of caveolae include cholesterol trans-
port (2, 3), endocytosis (4), potocytosis (5), and signal transduction
(6–9). Recent insights into the physiological roles of caveolae and
their primary coat proteins, caveolins, have been dissected in
genetically modified mice (10, 11). Caveolin-1 (Cav-1) and Cav-3
are dispensable during vascular and organ development but are
essential for caveolae formation in specialized cells including most
endothelia, adipocytes, and skeletalcardiac myocytes. In vitro data
have shown that signaling molecules can potentially interact with
Cav-1, and that interactions with Cav-1 can increase or decrease the
fidelity or magnitude of signaling (12–14). The ability of proteins to
localize in caveolae, in addition to direct interactions of proteins
with caveolins, has led to the hypothesis that caveolae may com-
partmentalize signaling in the plasma membrane and that the
interactions (direct and indirect) between resident proteins and
Cav-1 may fine-tune the signaling cascades.
Physiologically, the loss of caveolae results in impairment of
cholesterol homeostasis (15), insulin sensitivity (16), nitric oxide
(NO) (10, 11), calcium signaling (10), and cardiac function (17).
These studies validate the in vivo importance of caveolae and
caveolins beyond cell-based studies that are largely hampered by
operational definitions of biochemical fractions containing caveo-
lins and the lack of specificity inherent in reagents that remove
cellular cholesterol. Although caveolin knockout mice are useful
to delineate the importance of caveolae in a given response,
there are additional questions that are difficult to dissect,
because the loss of Cav-1 and Cav-3 abolishes both the caveolae
organelle as well as the pathways regulated by protein–protein or
protein–lipid interactions with the caveolins. To study how Cav-1
influences cardiovascular signaling in mice replete with caveo-
lae, we generated mice that overexpress Cav-1 in the endothelial
layer of blood vessels and examined different aspects of vascular
cell signaling and angiogenesis.
Materials and Methods
Generation of Endothelial-Specific Cav-1 Transgenic (TG) Animals.
Cav-1 TG mice were generated as described in ref. 18. Briefly,
canine Cav-1 was subcloned into the NotI site of the PEP8 plasmid
vector consisting of the pCDM8 backbone (Invitrogen), the 9.2-kb
murine preproET-1 5 flanking promoter, the SV40 intron poly(A)
signal, and a single NotI site by using standard techniques. The
plasmid, or PEP-Cav-1, was purified on a cesium chlorideethidium
bromide gradient. The plasmid was linearized by SpeI digestion and
subjected to agarose gel electrophoresis. The linearized plasmid was
then electroeluted from the gel, and DNA was used to generate TG
mice by using standard techniques.
Immunohistochemistry. Eight- to 10-week-old Cav-1 TG or WT
littermates were perfused with PBS for 5 min and then with 4%
paraformaldehyde for 5 min at physiological temperature and
pressure. Blood vessels were then harvested and diffusion-fixed
overnight at 4°C and then dehydrated in 30% sucrose overnight at
4°C. The vessels were then embedded, and 5-m sections were
stained for Cav-1. Cav-1 was visualized by using the VECTASTAIN
ABC kit (Vector Laboratories), followed by incubation with
NovaRed substrate (Vector Laboratories).
EM. Cav-1 TG mice or WT littermates were perfused for 10 min at
room temperature (RT) under anesthesia with oxygenated DMEM
through the left ventricle, followed by fixation by perfusion (10 min
at RT) with 2.5% glutaraldehyde and 3% paraformaldehyde in 0.1
M sodium cacodylate buffer (pH 7.3). Specimens were taken from
different tissues and trimmed into small blocks. The blocks were
immersed into fresh fixative (1 h at RT), washed twice (15 min at
RT) in 0.1 M cacodylate, postfixed in Palade’s OsO4 (1 h on ice),
en bloc-stained in Kellemberger’s uranyl acetate (overnight at RT),
dehydrated in graded ethanol, and embedded in LX112 resin (Ladd
Research Industries, Burlington, VT). Thin sections (50 nm) were
cut, stained with lead citrate, and examined and photographed
under an electron microscope (JEOL 1200EX or CM10, Phillips
Electronic Instruments, Mahwah, NJ). Caveolae number per m of
endothelial cell length was determined by counting the number
of plasmalemmal attached caveolae from 50 sections per animal per
tissue (n  3 mice per group).
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Aortic-Ring Assay. The thoracic aorta is dissected from male mice
(8–10 weeks old) and cut into cylindrical, 3-mm-long segments. The
rings are suspended by two tungsten wires mounted in a vessel
myograph system (Danish Myotechnologies, Aarhus, Denmark).
The aortas were bathed in oxygenated Krebs buffer and submitted
to a resting tension of 9.8 mN. After 60 min of equilibration with
frequent washings, concentration response curves for phenyleph-
rine (PE) were generated to determine vasoconstrictor responses.
To study vasodilator and L-nitro arginine methyl ester (L-NAME)
responses, the rings were preconstricted with a submaximal con-
centration of PE, and acetylcholine (ACh) (109 to 105 M),
sodium nitroprusside (SNP) (109 to 3 107 M), or L-NAME
(100 M) was injected at the plateau of the PE-induced contraction.
In Vivo Microvessel Pharmacology. In second-order branches off the
major vessel entering the cremaster muscle (2A arterioles), vaso-
constriction to PE (109 to 104 M), and vasodilation to ACh (109
to 104 M), bradykinin (109 to 105 M), and isoproteronol (1010
to 105 M) were measured in vivo by using intravital microscopy
(19). Arteriolar internal diameter was measured by video micros-
copy (resolution 2 m). Agonist-induced diameter changes were
tested in semirandom order by cumulative addition to the super-
fused physiological salt solution (137 mM NaCl4.7 mM KCl1.2
mM MgSO42 mM CaCl218 mM NaHCO3, equilibrated with 5%
CO295% N2) with at least 2 min between each dose.
Immunoprecipitation and Western Blot. Tissues for Western blot
analysis were flash-frozen, crushed, and resuspended in lysis buffer
[50 mM TrisHCl, pH 7.4100 mM NaCl0.1 mM EGTA0.1 mM
EDTA1% Triton X-1001 mM sodium orthovanadate20 mM
NaF1 mM Na4P2O71 mM Pefabloc SC and protease inhibitor
mixture (Roche Diagnostics); for Cav-1 immunoprecipitation; 10
mM Tris, pH 8.060 mM n-octyl -D-glucopyranoside150 mM
NaCl1 mM sodium orthovanadate20 mM NaF1 mM
Na4P2O71 mM Pefabloc10 g/ml aprotinin10 g/ml leupeptin].
Insoluble material was removed by centrifugation at 12,000  g for
10 min at 4°C. Fifty micrograms of protein from cell lysates was then
analyzed by Western blot analysis, or 500 g of protein from lysates
was immunoprecipitated for Cav-1 or VEGF receptor 2
(VEGFR2) and subjected to Western blot analysis.
Modified Mile’s Assay. Mice were anesthetized with ketamine
xylazine (60 mg/kg15 mg/kg i.m.), and a catheter was introduced
into the left jugular vein for administration of Evans blue (30
mgkg; Sigma). One minute after the administration of the dye,
VEGF (30 ng in 30 l) or saline was injected into the right and left
dorsal ear skin, respectively. After 30 min, the animals were killed
and perfused, and the ears were removed, dried in an oven at 55°C,
and weighed. Evans blue content of the ear was evaluated by
extraction with 500 l of formamide for 24 h at 55°C and measured
spectrophotometrically at 610 nm. Results were compared with a
standard curve of Evans blue in formamide.
Ear Angiogenesis. Ear angiogenesis studies are described in ref. 20.
An adenovirus vector encoding murine VEGF-A164 (AdVEGF;
108 plaque-forming units in 15 l) was injected s.c. into the ears of
8- to 12-week-old male mice. Contralateral ears were injected with
an adenovirus encoding green fluorescent protein (AdGFP). After
6 days, mice were killed and the ears were removed and embedded.
Frozen sections (5 m) were immunostained with an antibody
against the endothelial-cell marker PECAM (platelet-endothelial
cell adhesion molecule) and quantified by immunofluorescence.
Hind-Limb Ischemia. Male mice (8–10 weeks old) were anesthetized
with ketaminexylazine (60 mg/kg15 mg/kg i.m.), and a skin
incision was made on the inside of the hind limb to expose the
muscles of the upper and lower hind limb. The proximal femoral
artery including the superficial and deep branch and the distal
portion of the saphenous artery were ligated and dissected. Flow
was measured in the muscle of the lower limb of the ischemic (left
leg) and nonischemic (right leg) mice by placing a deep laser
Doppler probe directly on the gastrocnemius muscle. This probe
penetrates 1 mm into the tissue and measures blood flow through-
out the muscle. Flow measurements were made before and imme-
Fig. 1. Generation of endothelium-
specific TG mice. (A) Construct used
for generating the Cav-1 TG mice. The
canine Cav-1 cDNA was driven by the
preproendothelin promoter. (B) Ex-
pression of the transgene vs. endog-
enous Cav-1. Primers specific for ca-
nine Cav-1 recognize the plasmid
containing canine Cav-1 (pCCav-1)
and TG Cav-1 (Cav-1 TG) but not en-
dogenous Cav-1 (WT littermate). (C)
The presence of both WT and trans-
gene Cav-1 by RT-PCR in various tis-
sues. pMCav-1 is the murine Cav-1
cDNA (D) The increased expression of
Cav-1 and Cav-2 in aortic extracts
from two TG lines (TG-1 and TG-2),
compared with C57Bl6 or WT litter-
mates. (E) Immunoprecipitation of
Cav-1 from TG lung extracts increases
the amount of eNOS co-associated
(Lower, total Cav-1 immunoprecipi-
tated; Upper, coassociated eNOS). (F)
Immunohistochemical evidence for
expression of Cav-1 transgene in the
endothelium. WT and Cav-1 TG aortic
sections were stained with a Cav-1
mAb. Note the presence of intense
labeling of Cav-1 in the EC, with little
difference in the intensity of Cav-1 in
underlying smooth muscle.











diately after surgery, then again at 2 and 4 weeks postsurgery.
Skeletal muscle isolated from the ischemic leg 4 weeks after femoral
ligation was fixed with methanol and then embedded in paraffin.
Multiple sections (5 m) were stained for PECAM-1 (Pharmingen)
and visualized by using the VECTASTAIN ABC kit followed by
incubation with NovaRed substrate (Vector Laboratories).
Assessment of in Vivo Phosphorylation. Male mice (8–12 weeks old)
were anesthetized with ketaminexylazine (60 mg/kg15 mg/kg
i.m.), and a catheter was introduced into the left jugular vein for
administration of VEGF. Either human VEGF165 (2 mg) or saline
was injected and allowed to circulate for 5 min. The animal was then
perfused with 5 ml of PBS supplemented with phosphatase inhib-
itors (1 mM sodium orthovanadate20 mM NaF1 mM Na4P2O7),
after which the lungs were harvested for Western blot analysis.
Results and Discussion
Cav-1 TG mice were generated by using SpeI-linearized prepro-
endothelin-1 promoter to drive the Cav-1 transgene (Fig. 1A) (18).
Founder mice harboring the transgene were identified by PCR of
genomic DNA isolated from tail biopsies at age 3–4 weeks (Fig.
1B). Fourteen founders were independently bred to C57BL6J
mice to assess stable transmission of the transgene. Eight founders
stably transmitted the transgene after three rounds of backcrossing
to C57BL6J mice. All experiments were performed with heterozy-
gous Cav-1 TG mice and their non-TG littermates as controls.
There were no apparent morphological abnormalities in Cav-1 TG
mice. The mice had normal body weights, heart-to-body weight
ratios, heart rates, and blood pressure (Table 1), and serum NO
levels (measured as NOx) in the Cav-1 TG mice were not signifi-
cantly different from those in WT mice. Male and female mice
appeared equally fertile, and there were no differences in grooming
behavior or growth rate, compared with WT littermates.
RT-PCR to detect canine Cav-1 mRNA revealed transgene
expression in the heart, lung, aorta, brain, and liver of Cav-1 TG but
not WT mice (Fig. 1C). Western blot analysis revealed that Cav-1
is 2-fold overexpressed in aorta of the Cav-1 TG mice from two
different founders bearing the Cav-1 transgene (Fig. 1D). Addi-
tionally, Cav-2 is up-regulated in the Cav-1 TG mice, consistent with
data indicating that expression of Cav-1 is important for the stability
of Cav-2 (Fig. 1D) (10, 11). It is important to note that the relative
overexpression of Cav-1 in the endothelium is greater than can be
demonstrated by Western blot analysis because the endothelium is
a single cell layer, compared with several layers of smooth muscle,
which also express Cav-1. Endothelial NO synthase (eNOS) levels
were not changed in the Cav-1 TGs, compared with WT littermates
(Fig. 1D), however, more eNOS was associated with Cav-1 in the
Cav-1 TGs as assessed by coimmunoprecipitation of eNOS with
Cav-1 isolated from lung extracts (Fig. 1E). Immunohistochemical
staining of aorta revealed overexpression of the transgene in the
endothelium of Cav-1 TG mice (Fig. 1F), whereas staining for
Cav-1 in the smooth muscle layer is similar between Cav-1 TGs and
WT littermates.
Cav-1 is responsible for caveolae biogenesis in the endothelium
in vivo, because these organelles are absent in mice deficient in
Cav-1 (10, 11). Thus, we quantified caveolae number in the heart
and aorta from WT and Cav-1 TG mice. Transmission electron
micrographs were collected, and caveolae attached to the luminal
and abluminal plasma membranes of endothelial cells were quan-
tified. Fig. 2A shows electron micrographs of coronary capillaries
from WT and Cav-1 TG mice and quantification of caveolae
number in coronary capillaries (Fig. 2B). Interestingly, there were
no significant difference in caveolae number in Cav-1 TG mice,
compared with WT littermates. Qualitatively similar results were
obtained in aorta and coronary arterioles (data not shown). These
data in vivo are unlike studies in cultured cells (which have 100-fold
fewer caveola per m of membrane) where acute overexpression of
Cav-1 increases caveolae number (21–25). Thus, in vivo, the number
of endothelial caveola in the endothelia of vessels examined appears
maximal, and organelle number is not regulated by further increases
in Cav-1 protein levels.
Next, we examined whether overexpression of Cav-1 regulates
vascular functions. Because there is biochemical and genetic sup-
port for eNOS regulation by a direct interaction with Cav-1 (14, 26,
27), we examined the effect of endothelial Cav-1 overexpression on
eNOS function in large blood vessels by quantifying the vascular
reactivity of aortic rings to the endothelium-dependent vasodilator
ACh and to the NOS inhibitor L-NAME. Consistent with Cav-1
being an endogenous inhibitor of eNOS activity, aorta from Cav-1
TG mice were less responsive to ACh. Fig. 3A shows typical
experimental traces of aortic rings from WT and Cav-1 TG mice.
Higher concentrations of ACh are required to elicit relaxation of
the isolated aorta. Analysis of the dose–response relationships in
the two strains reveals that the EC50 is shifted nearly 10-fold in the
Cav-1 TG animals (EC50 in WT aorta  4.91  0.06  108M; EC50
in Cav-1 TG aorta  3.93  0.05  107M) (Fig. 3B). In addition,
basal NO release in Cav-1 TG mice also was diminished, as depicted
in the trace in Fig. 3C. Vessels were preconstricted with a submaxi-
mal dose of PE, and the NOS inhibitor L-NAME (100 M) was
added at the peak of the constriction to remove endogenous NO.
Table 1. Baseline parameters and hemodynamics of wild-type
littermates and Cav-1 TG mice
WT Cav-1 TG
Mean SEM Mean SEM
Body weight, g 26.43 0.46 24.98 0.57
Heart, mgbody weight, g 4.90 0.18 5.05 0.11
MAP, mmHg* 105.38 6.03 103.02 5.26
Heart rate, beats per min 207.75 12.07 204.83 14.30
Plasma NOx, mM 15.28 1.30 13.54 0.54
Data are mean  SEM, with n  9 per group.
*1 mmHg  133 Pa.
Fig. 2. TG expression of Cav-1 in endothelium does not change caveolae
number. (A) Representative transmission electron micrographs of coronary
capillaries from WT or TG mice. (Insets) Magnifications (4) to demonstrate
the caveolae anatomy. (Scale bar: 1 m.) (B) Quantification of luminal and
abluminal caveolae structures. Data (mean  SEM) are from 50 sections per
mouse with n  3 mice per group.
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L-NAME caused a further constriction of WT vessel, resulting in
an increase in isometric tension reflecting the removal of basally
released NO. However, constriction of the vessel in response to
L-NAME was significantly attenuated in Cav-1 TG mice (Fig. 3D).
These effects on vasomotion occur selectively in the endothelium
because the vasoconstrictor action of PE and the NO donor drug
SNP elicit similar responses in the two strains (Fig. 3 E and F).
Collectively, these data support the idea that a major role of Cav-1
in endothelium is to regulate eNOS function.
In contrast, when using intravital microscopy to determine the
vascular reactivity of small arterioles (100 m or less) in the
cremaster muscle, there were no differences in the diameters or
responsiveness of the microcirculatory bed to standard pharmaco-
logical stimuli between the two strains (Table 2). These results are
not surprising, because it is recognized that other pathways (such as
endothelial-derived hyperpolarizing factor signaling through gap-
junctional coupling) are the predominate vasodilatory pathways in
the mouse microcirculation (28, 29).
The role of Cav-1 or caveolae in regulating vascular barrier
function and permeability is not well understood. Caveolae are
highly abundant in capillaries and in postcapillary venules. In
Cav-1(/) mice, the loss of caveolae results in reduced steady-
state plasma albumin levels and increases in the clearance of
radioactive albumin, suggesting that the vessels are hyperpermeable
(30). To assess whether Cav-1 can influence vascular leakage, we
examined the ability of VEGF to induce the extravasation of Evans
blue in the ears of WT vs. Cav-1 TG mice. Mice were injected i.v.
with Evans blue (which binds to plasma albumin), and the dye was
allowed to circulate for 5 min. VEGF (30 ng) was then injected into
the right ear of the mouse, and saline was injected into the left ear.
After 30 min, mice were killed, and Evans blue extravasation into
the interstitium was quantified. As illustrated in Fig. 4A, Cav-1
overexpression reduces VEGF-stimulated Evans blue extravasation
into the ear interstitium, compared with responses in WT litter-
mates. Thus, endothelial-specific Cav-1 overexpression reduced
VEGF-stimulated vascular permeability, presumably by attenuat-
ing eNOS-dependent blood flow andor permeability changes
evoked by the angiogenic cytokine.
Considering that VEGF-mediated vascular permeability is a key
component of the angiogenic process in vivo, we assessed whether
expression of Cav-1 influenced angiogenesis. WT and Cav-1 TG
mice were injected with equal multiplicity of infection of adenoviral
adVEGF164 into the right ear and, as a control, AdGFP into the
left ear. After 6 days, the extent of angiogenesis was determined
through staining for the endothelial marker, PECAM-1. Fig. 4B
shows greater density of PECAM-1-labeled structures in WT mice,
compared with Cav-1 TG mice. Quantification of the extent of
angiogenesis shows that Cav-1 overexpression reduces VEGF-
mediated angiogenesis by 40%, compared with littermate controls
(Fig. 4C).
Recent studies suggest that localization of VEGFR2 to caveolae
may be an important factor in VEGF-induced signaling (31). To
determine whether the lack of VEGF-driven permeability and
angiogenesis were due to defects in VEGF-induced signaling
pathways, we determined the in vivo phosphorylation of targets
downstream of VEGFR activation. Age-matched littermates and
Cav-1 TG mice were injected i.v. with VEGF (2 mg). After 5 min,
lungs were excised and processed for semiquantitative Western blot
analysis (32). As seen in Fig. 4D, VEGF stimulated the tyrosine
phosphorylation of the endothelial VEGFR, VEGFR2, in both WT
and Cav-1 TG mice, suggesting that impairment of signaling in Cav
TG mice is not a direct effect on VEGFR2 localization or dimer-
ization (Fig. 4D). In contrast, VEGF-mediated phosphorylation of
the protein kinase Akt (on serine 473) and the Akt substrate, eNOS
(on serine 1179), was significantly reduced in VEGF-treated Cav-1
TG mice, compared with littermate controls. The inhibitory effect
Fig. 3. Endothelial expression of Cav-1 impairs eNOS-dependent vasodilation. (A) Representative bioassay trace from WT littermate (intermittent line) and
Cav-1 TG (solid line) mice. Aortic rings were precontracted with PE, and ACh-induced dilations were examined. (B) Statistical analysis of the full dose–response
curves to ACh demonstrates a 10-fold change in the EC50 value for ACch in Cav-1 TG mice. (C) Basal eNOS activation is reduced in Cav-1 TG. Vessels were contracted
with PE and then incubated with a NOS inhibitor L-NAME to remove basal NO synthesis. (D) Cav-1 TG mice show a deficiency in basal NO synthesis. (E and F) The
deficit in eNOS activation does not influence the ability of the vessels to contract to PE or to relax to the NO donor drug, SNP. Data are mean  SEM, with n 
5 animals and two aortic rings per animal. *, P  0.05.
Table 2. EC50 determined by intravital microscopy in the
cremaster muscle
WT Cav-1 TG
Mean SEM Mean SEM
Phenylephrine 1.50  106 6.20  107 2.97  106 1.20  106
Acetylcholine 7.40  106 3.34  106 5.67  106 2.14  106
Bradykinin 4.69  107 2.01  107 7.14  107 3.70  107
Isoproterenol 3.82  109 5.53  1010 1.21  109 3.05  1010
Potency of vasoconstrictors (phenylephrine) and vasodilators (acetylcho-
line, bradykinin, and isoproterenol) in the microcirculation of WT littermates
and Cav-1 TG mice. Data are mean  SEM, with n  7 per group.











of Cav-1 expression on the Akt-eNOS pathway was specific, because
VEGF-stimulated phosphorylation of ERK12 was not reduced
but enhanced in the Cav-1 TGs, compared with littermates. This
suggests that, in endothelial cells, Cav-1 differentially regulates
VEGF-induced signal transduction, and that diminution of the
AkteNOS axis provides a plausible mechanism to explain the
defects in vasodilation, permeability, and angiogenesis in this
model. Finally, as an independent assay to determine the role of
endothelial Cav-1 in angiogenesis, we induced tissue ischemia in the
hind limb of WT littermates and Cav-1 TG mice. In this model,
ligation of the left femoral artery triggers tissue ischemia followed
by an increase in arteriogenesis and angiogenesis (33). After
surgery, blood flow was reduced to the same extent in the ischemic
legs of WT littermate mice and Cav-1 TG. However, blood flow
recovery, reflecting arteriogenesis and angiogenesis, was signifi-
cantly reduced at 2 and 4 weeks postsurgery in Cav-1 TG mice (Fig.
5A). To quantify the clinical differences between the Cav-1 TG and
WT littermates, a clinical score index between 0 and 4 was assigned
to each mouse (Fig. 5B). Immediately after surgery, the clinical
score of both groups was 1, indicating that the mice had gait
abnormalities and paleness of the foot due to lack of blood flow.
WT mice mostly recovered by 2 weeks and had a clinical score of
0 by 4 weeks, indicating complete recovery. All of the Cav-1 TG
mice had a clinical score of 2 by 2 weeks, indicating partial necrosis
Fig. 4. VEGF-mediated functions are
reduced in Cav-1 TG mice. (A) Cav-1 TG
mice exhibit reduced (30 min) VEGF-
stimulated vascular leakage. Data are
mean  SEM (n  6). (B) PECAM-1-
positive vascular structures in the ears
of WT (Left) or Cav-1 TG (Right) mice
injected with AdVEGF (after 6 days).
(C) AdVEGF-mediated angiogenesis
was reduced in Cav-1 TG (mean 
SEM, with n  6 animals per group,
and 10 fields were quantified for each
ear). (D) VEGF-mediated signal trans-
duction to Akt and eNOS are reduced
in Cav-1 TG mice. Mice were injected
with saline or VEGF, and lung tissue
was processed for Western blot anal-
ysis. The numbers below represent
densitometric evaluation of the data,
with a value of 1.0 reflecting the basal
level of phosphorylation of each sig-
naling protein (FLK, eNOS, Akt, and
ERK, respectively). Similar results were
obtained in three additional experi-
ments. *, P  0.05.
Fig. 5. Ischemia-induced arteriogenesis and
angiogenesis are impaired in Cav-1 TG mice. (A
and B) Arteriectomy was performed in Cav-1
TG and WT mice, and blood flow (A) and clin-
ical index (B) were quantified over time. Data
are mean  SEM (n  6). (C) The inflamed,
necrotic foot seen in nonischemic (Upper Left)
and ischemic (Upper Right) Cav-1 TG mice,
compared with littermate controls (Lower). (D)
The reduction in blood-flow recovery and clin-
ical outcome were attributable to a decrease
in lower-limb angiogenesis. Data are mean 
SEM, with n  6 animals per group. Four fields
per section and five sections per animal were
quantified. *, P  0.05.
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of their foot due to the lack of blood flow, and this loss did not
recover at the 4-week time point (Fig. 5C). Finally, we quantified
the extent of angiogenesis in the lower limb by quantitative PECAM
staining. As seen in Fig. 5D, there was a 35% decrease in PECAM-
1-positive capillaries in the ischemic gastrocnemius muscle of the
TG mice, compared with littermates, suggesting that the lack of
blood flow recovery was due to defects in angiogenesis.
Our study using EC-specific Cav-1 TG mice raises several
important questions regarding the regulation and functions of
Cav-1 and caveolae in vivo. Surprisingly, despite clear phenotypes
of TG expression on vascular functions (NO production, VEGF-
stimulated permeability and angiogenesis, VEGF signaling, and
ischemia-triggered angiogenesis), these results occur in the absence
of obvious changes in caveolae number analyzed by quantitative
EM. Our data suggest that the number of caveolae in the endo-
thelium in vivo is not limited by the levels of Cav-1, as is typically
seen in many cultured cell systems. Because fluid shear stress
increases Cav-1 levels and caveolae number in cultured endothelial
cells (34), perhaps the continual shear stress determined by blood
flow in vivo maintains steady-state levels of caveolae in vivo. In
addition, our data are consistent with results showing an increase
in eNOS activation and leakiness of vessels in mice lacking Cav-1
and caveolae (30), because endothelial-specific expression of Cav-1
reduces eNOS activation, NO-dependent vascular function, and
VEGF-stimulated permeability. However, our data differ from
studies in Cav-1(/) mice that show decreased ischemia-induced
angiogenesis (35), whereas in the present study, both VEGF-and
ischemia-mediated angiogenesis are reduced by EC overexpression
of Cav-1. The mechanism of impaired arteriogenesisangiogenesis
in Cav-1(/) mice appears also to be due to defective VEGFR
signaling to ERK, Akt, and eNOS. Interestingly, the authors show
in vitro that, both in Cav-1(/) endothelial cells and in endothelial
cells reconstituted with higher levels of Cav-1, VEGF signaling is
defective, although the mechanism for these effects is unclear.
Perhaps in the Cav-1(/) mice, the loss of the caveolae organelle
impairs spatial activation of the VEGFR, and in our study, the
overexpression of Cav-1 does not influence organelle turnover but
directly inhibits pathways downstream of the VEGFR receptor by
a protein–protein interaction. The decreases in VEGF-mediated
functions in Cav-1 TG mice were not due to changes in VEGFR2
tyrosine phosphorylation or coupling to ERK but occur through
negative regulation of the PI-3KAkteNOS signaling module,
which diminishes the ability of VEGF to promote cell migration,
organization, and NO production (36, 37). Indeed, in postnatal
mice, eNOS is critical for the actions of exogenous VEGF and for
ischemia-mediated arteriogenesis (33). Thus, the impaired VEGF
permeability and angiogenesis is consistent with the established
inhibitory action of Cav-1 on eNOS (38, 39) and tyrosine kinase-
associated phosphatidylinositol 3-kinase activity (40). Our data
strongly support the concept that Cav-1 can indeed regulate cellular
functions through protein–protein interactions and provide an
additional model to define the functionally relevant roles of Cav-1
in the endothelium, in vivo.
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